Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor probably leads to lower adverse events: medications ceased due to adverse events compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review
Antihypertensive medication · chronic HD
1 finding from 1 review
Antihypertensive medication · chronic HD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Antihypertensive medication · chronic HD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
All symptomatic CMV disease · solid organ transplant recipients
Antiviral prophylaxis leads to lower CMV disease: all symptomatic CMV disease compared with placebo or no treatment (high certainty).
1 finding from 1 review
Death associated with CMV disease · solid organ transplant recipients
Ganciclovir showed no clear difference in death due to CMV disease compared with aciclovir (moderate certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Ganciclovir showed no clear difference in all‐cause death compared with aciclovir (moderate certainty).
1 finding from 1 review
Acute rejection · solid organ transplant recipients
Ganciclovir showed no clear difference in acute rejection compared with aciclovir (high certainty).
1 finding from 1 review
Graft loss · solid organ transplant recipients
Ganciclovir showed no clear difference in graft loss compared with aciclovir (moderate certainty).
1 finding from 1 review
Opportunistic infections: other viral infections · solid organ transplant recipients
Ganciclovir showed no clear difference in opportunistic infections: other viral infections compared with aciclovir (moderate certainty).
1 finding from 1 review
Leucopenia · solid organ transplant recipients
Ganciclovir may leads to higher leucopenia compared with aciclovir (low certainty).
1 finding from 1 review
Kidney dysfunction · solid organ transplant recipients
Ganciclovir showed no clear difference in kidney dysfunction compared with aciclovir (moderate certainty).
1 finding from 1 review